Davunetide

At a glance

Overview

Davunetide contains the sequence NAPVSIPQ, a short fragment of activity-dependent neuroprotective protein (ADNP). ADNP-related laboratory research examines proteins that support neuronal structure and connections. The human development program used an intranasal formulation in different disease populations, including amnestic mild cognitive impairment and progressive supranuclear palsy (PSP). These are separate clinical questions: memory-test performance in people with cognitive impairment does not establish treatment of a progressive movement disorder. Early task-specific signals encouraged further investigation, but the composite memory result and later PSP primary outcomes remained negative. Experimental ADNP-related programs require their own evidence.

Supporting sources [1] [2] [3] [4]

How it works

Preclinical experiments linked NAP to microtubule end-binding proteins EB1 and EB3, which help organize the cell's structural scaffold. In the original 2014 study, reducing EB1 or EB3 blocked NAP-associated cell protection, and reducing EB3 prevented an effect on a dendritic-spine marker. These observations support a laboratory mechanism. They do not demonstrate that the same process produces meaningful clinical benefit in a human brain.

Supporting sources [1] [2] [3] [4]

A substantial negative trial

A 52-week randomized, double-blind study assigned 313 participants to davunetide or placebo. Neither the PSP Rating Scale nor the activities-of-daily-living endpoint improved relative to placebo. This was a meaningful test of the proposed treatment, rather than an absence of research. It is inappropriate to describe the peptide as proven neuroprotection on the basis of cell experiments while omitting this result.

Supporting sources [1]

What tolerability data can show

The MCI study reported generally acceptable tolerability. In the larger PSP study, nasal discomfort, runny nose, and nosebleeds were more frequent with davunetide; serious adverse events occurred in both groups. Trial surveillance informs the particular preparation and population studied. It cannot establish the safety of unrelated formulations or chronic use in healthy people.

Supporting sources [1] [2]

What the earlier memory study found

A randomized 12-week study enrolled 144 adults with amnestic mild cognitive impairment. The treatment groups did not differ significantly on the composite cognitive memory score. Two individual memory or attention tasks produced signals that the authors considered worth further investigation. Those selective findings do not establish an overall memory benefit, prevention of Alzheimer's disease, or effectiveness in healthy people.

Supporting sources [2]

How to read newer development claims

Cell protection, a selected cognitive task, and everyday functioning are different endpoints. A new indication, formulation, or biomarker finding requires evidence appropriate to that claim. Failure in one disease does not prove failure in every condition, but a new hypothesis or laboratory mechanism does not reverse a completed negative clinical trial. Later programs must establish their own benefits and risks.

Supporting sources [1] [2] [3]